DC Fine Chemicals has laid the first stone at its new €7 million headquarters in Terrassa, Spain. This comprises a 3,050 m2 building on a 7,300 m2 site, which will allow for total storage without the need for external warehouses and capacity of up to 1,900 pallets on seven levels, compared to the 900 in the former warehouse.
Germany-based Evonik and Heraeus Precious Metals have announced that they are collaborating to expand their range of services for HPAPIs. They intend to build a fully integrated offering from the pre-clinical stage to commercial manufacturing, with streamlined transfer between small- and large-scale production between their respective sites.
Heraeus’s Pharmaceutical Ingredients business offers customised services for both earlier and later clinical phases and smaller to mid-volume HPAPI commercial products. It claims to be the world’s leading supplier of platinum-based HPAPIs.
Japan’s DIC Corporation has acquired PCAS Canada from PCAS, a legacy subsidiary of Seqens, for an enterprise value of €82 million, and has renamed it Innovation DIC Chimitroniques. This follows agreement by both boards and the workers’ council.
PCAS Canada has a facility near Montreal producing photoresists for semiconductor photolithography, an area in which DIC expects substantial growth. DIC will combine these with its own syntheis technologies and will continue to invest in the site.
Italian CDMO Olon has announced the start of a construction on a €22 million facility for the production of ultra-potent compounds. These are aimed for use mainly as payloads and payload-linkers for antibody-drug conjugates (ADCs) at its site at Rodano, near Milan. The facility will reach containment OEB Level 6, with a target occupational exposure level (OEL) of 10 ng/m3.
Global Healthcare Opportunities (GHO), a European specialist investor in healthcare, and Partners Group, a global private markets firm, have both invested in Sterling Pharma Solutions, a CDMO owned by GHO. The exact amounts have not been disclosed.
Evonik has begun construction of a new production plant for alkoxides on Jurong Island in Singapore. Described as a “mid double-digit million-euro investment” this will complement sites in Germany, Argentina and the US, supplying the growing Asia-Pacific market when it comes onstream at the end of 2024. The aim is to achieve zero Scope 1 and 2 carbon emissions.
CordenPharma is entering synthetic oligonucleotide manufacturing via an investment at its CordenPharma Colorado site. This will draw on its solid-phase peptide manufacturing experience and downstream processing capabilities to offer a fully integrated drug substance and drug product offer.
